https://betafinch.comenInvesting2026 Beta Finchhttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/710e5e9774fc3862b259c9bd14e3e065.jpghttps://betafinch.comWed, 22 Jul 2026 07:14:09 +0000Beta FinchBeta Finchcontact@betafinch.comAI-powered earnings call analysis for Intuitive Surgical (ISRG). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.falsetrueepisodichttps://www.spreaker.com/episode/intuitive-surgical-q2-2026-earnings-analysis--73101513https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper.

ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%.

JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters.

ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1.

JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait.

ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it.

JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery.

ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures.

JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time.

ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance.

JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch.

ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago.

JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already.

ALEX: One thing that stood out to me in t

This episode includes AI-generated content.]]>ISRG-Q2-2026-enWed, 22 Jul 2026 07:13:16 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026...https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper.

ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%.

JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters.

ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1.

JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait.

ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it.

JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery.

ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures.

JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time.

ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance.

JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch.

ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago.

JORDAN: And then there's da Vinci 5, which...]]>418falsefullhttps://www.spreaker.com/episode/intuitive-surgical-q4-2025-earnings-analysis--70233539
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're unpacking Intuitive Surgical's Q4 2025 results - and folks, this robotics giant just delivered some seriously impressive numbers.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, where do we even start with these results? Intuitive absolutely crushed it this quarter. We're talking about a company that just crossed the 20 million patient milestone since 1997 and shows no signs of slowing down.

**ALEX:** Let's hit the headline numbers first. Revenue grew 21% to hit $10.1 billion for the full year - that's massive growth for a company this size. And quarterly revenue was up 19% to $2.87 billion. But Jordan, what really caught my eye was the procedure growth.

**JORDAN:** Absolutely. Total procedures grew 19% for the year to over 3.1 million. That's not just impressive - it's accelerating adoption of robotic surgery worldwide. Da Vinci procedures specifically were up 18%, with their single-port procedures exploding 87% year-over-year. That tells me surgeons are really embracing these newer technologies.

**ALEX:** And geographically, the story gets even better. US procedures grew 15%, but international was the real star - up 23% with particularly strong performance in Europe at 21%, Asia at 24%, and rest of world markets at 27%. It's becoming a truly global story.

**JORDAN:** What I found fascinating was the capital equipment side. They placed 1,721 da Vinci systems in 2025, including 870 of their newest da Vinci 5 systems. The demand for upgrades is clearly there, especially with the dual console systems for training and mentoring. That speaks to hospitals really investing in their robotic surgery capabilities long-term.

**ALEX:** Let's talk margins for a second. Operating margins came in at 37%, which is solid, though they're dealing with some headwinds. CEO David Rosa mentioned tariffs are hitting them for about 95 basis points, plus they're investing heavily in R&D and scaling manufacturing. But they're managing it well with cost efficiency initiatives.

**JORDAN:** The tariff impact is significant - they're forecasting 120 basis points of impact in 2026, up from about 65 basis points in 2025. That's a real cost pressure they're navigating. But here's what's interesting - they're still guiding for gross margins of 67-68% in 2026, essentially flat despite these headwinds.

**ALEX:** Now, one of the most exciting developments from this call was the FDA clearance for cardiac procedures on the da Vinci 5. Jordan, this could be huge, right?

**JORDAN:** Potentially massive, Alex. They performed about 17,000 cardiac procedures globally in 2025, which sounds small, but Rosa mentioned the addressable market for da Vinci 5 in just the US and Korea is around 160,000 procedures annually. Cardiac surgery is complex, high-value work, so even modest penetration could move the needle significantly.

**ALEX:** The Q&A session revealed some really interesting strategic directions. They're making a big push into ambulatory surgery centers - ASCs. Rosa explained they're targeting higher-volume ASCs, particularly those affiliated with existing hospital customers where surgeons are already da Vinci trained.

**JORDAN:** That ASC strategy is smart. About 70% of the ASC opportunity is with their existing IDN customers, so they have built-in relationships and trained surgeons. They're using their refurbished XI systems - the "XIR" - as the entry point, which gives them a lower-cost option for price-sensitive ASC market.

**ALE

This episode includes AI-generated content.]]>ISRG-Q4-2025-enMon, 23 Feb 2026 18:31:18 +0000trueBeta Finch# Beta Finch Podcast Script: Intuitive Surgical Q4 2025 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're unpacking Intuitive Surgical's Q4 2025 results - and folks, this robotics giant just delivered some seriously impressive numbers.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, where do we even start with these results? Intuitive absolutely crushed it this quarter. We're talking about a company that just crossed the 20 million patient milestone since 1997 and shows no signs of slowing down.

**ALEX:** Let's hit the headline numbers first. Revenue grew 21% to hit $10.1 billion for the full year - that's massive growth for a company this size. And quarterly revenue was up 19% to $2.87 billion. But Jordan, what really caught my eye was the procedure growth.

**JORDAN:** Absolutely. Total procedures grew 19% for the year to over 3.1 million. That's not just impressive - it's accelerating adoption of robotic surgery worldwide. Da Vinci procedures specifically were up 18%, with their single-port procedures exploding 87% year-over-year. That tells me surgeons are really embracing these newer technologies.

**ALEX:** And geographically, the story gets even better. US procedures grew 15%, but international was the real star - up 23% with particularly strong performance in Europe at 21%, Asia at 24%, and rest of world markets at 27%. It's becoming a truly global story.

**JORDAN:** What I found fascinating was the capital equipment side. They placed 1,721 da Vinci systems in 2025, including 870 of their newest da Vinci 5 systems. The demand for upgrades is clearly there, especially with the dual console systems for training and mentoring. That speaks to hospitals really investing in their robotic surgery capabilities long-term.

**ALEX:** Let's talk margins for a second. Operating margins came in at 37%, which is solid, though they're dealing with some headwinds. CEO David Rosa mentioned tariffs are hitting them for about 95 basis points, plus they're investing heavily in R&D and scaling manufacturing. But they're managing it well with cost efficiency initiatives.

**JORDAN:** The tariff impact is significant - they're forecasting 120 basis points of impact in 2026, up from about 65 basis points in 2025. That's a real cost pressure they're navigating. But here's what's interesting - they're still guiding for gross margins of 67-68% in 2026, essentially flat despite these headwinds.

**ALEX:** Now, one of the most exciting developments from this call was the FDA clearance for cardiac procedures on the da Vinci 5. Jordan, this could be huge, right?

**JORDAN:** Potentially massive, Alex. They performed about 17,000 cardiac procedures globally in 2025, which sounds small, but Rosa mentioned the addressable market for da Vinci 5 in just the US and Korea is around 160,000 procedures annually. Cardiac surgery is complex, high-value work, so even modest penetration could move the needle significantly.

**ALEX:** The Q&A session revealed some really interesting strategic directions. They're making a big push into ambulatory surgery centers - ASCs. Rosa explained they're targeting higher-volume ASCs, particularly those affiliated with existing hospital customers where surgeons are already da Vinci trained.

**JORDAN:** That ASC strategy is smart. About 70% of the ASC opportunity is with their existing IDN customers, so they have built-in relationships and trained surgeons. They're using...]]>572falsefullhttps://www.spreaker.com/episode/coming-soon-beta-finch-en--70092151
This episode includes AI-generated content.]]>ISRG-coming-soon-enTue, 17 Feb 2026 04:47:59 +0000trueBeta FinchStay tuned for AI-powered earnings analysis from Beta Finch.
This episode includes AI-generated content.]]>121falsefull